Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Elucidating the role of affective disorders in the onset and progression of Alzheimer's disease

FY 2015-16

Summary
Anxiety and depression are associated with increased risk of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) as well as accelerated shrinking of brain regions affected by AD. However, it is not yet know whether anxiety and depression may be causing accelerated AD pathology, or whether these disorders may be caused by early AD pathology that warns of disease onset and progression. A candidate factor explaining the manifestation of anxiety and depressive symptoms prior to the detection and progression of AD is the very early AD-related damage that occurs in a brain structure called the locus coeruleus. This structure is responsible for producing and distributing a chemical in the brain called norepinephrine, which is related to anxiety and depressive symptoms as well as AD pathology. Damage to the locus coeruleus early in the disease process may cause anxiety and depressive symptoms before AD-defining signs and symptoms are present. This study will examine whether volume loss in the locus coeruleus explains the relationship between anxiety and depressive symptoms and AD onset and progression. If it is found that damage to the locus coeruleus (and in turn, norepinephrine availability in the brain) mediates the relationship between anxiety/depressive symptoms and AD pathology, we will have a potential target for treatments to reduce anxiety and depressive symptoms among individuals affected by MCI and AD and potentially stave off accelerated progression of the disease.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
349937
Name
Terpstra Alexander R
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating the role of affective disorders in the onset and progression of Alzheimer's disease
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Affective Disorders; Alzheimer'S Disease; Anxiety; Depression; Neurodegeneration; Neuroimaging
Abstract
Anxiety and depression are associated with increased risk of progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease (AD) as well as accelerated shrinking of brain regions affected by AD. However, it is not yet know whether anxiety and depression may be causing accelerated AD pathology, or whether these disorders may be caused by early AD pathology that warns of disease onset and progression. A candidate factor explaining the manifestation of anxiety and depressive symptoms prior to the detection and progression of AD is the very early AD-related damage that occurs in a brain structure called the locus coeruleus. This structure is responsible for producing and distributing a chemical in the brain called norepinephrine, which is related to anxiety and depressive symptoms as well as AD pathology. Damage to the locus coeruleus early in the disease process may cause anxiety and depressive symptoms before AD-defining signs and symptoms are present. This study will examine whether volume loss in the locus coeruleus explains the relationship between anxiety and depressive symptoms and AD onset and progression. If it is found that damage to the locus coeruleus (and in turn, norepinephrine availability in the brain) mediates the relationship between anxiety/depressive symptoms and AD pathology, we will have a potential target for treatments to reduce anxiety and depressive symptoms among individuals affected by MCI and AD and potentially stave off accelerated progression of the disease.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Terpstra, Alexander R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~